Harmony Medical (HKEX: 0370) has disclosed that its affiliate Hua Jian Medical is partnering with Renhe Worldwide, a wholly-owned arm of Renhe Pharmaceutical, to construct a brand new real-world asset (RWA) platform for over-the-counter (OTC) medication.
The enterprise is being described as the primary vertical RWA system devoted to OTC prescribed drugs, with the goal of streamlining provide chains and bettering transparency in China’s quickly rising OTC market.
Tokenizing OTC Medicine for Safe, Actual-Time Buying and selling
The undertaking remains to be in growth, however the corporations stated it’s going to tokenize OTC pharmaceutical belongings, enabling safe, traceable, and real-time transactions between producers, distributors, and retailers.
By transferring drug inventories and transactions onto blockchain rails, the companions count on to chop inefficiencies, decrease prices, and enhance compliance with regulatory requirements, whereas giving market contributors extra confidence in product authenticity.
Associated: RWA Sector Hits File $25B Worth, Led by Personal Credit score and U.S. Treasuries
Renhe’s Position in Tech Infrastructure
Renhe Worldwide brings its background in digital transformation and blockchain adoption to the initiative. Its position is concentrated on growing a scalable and safe know-how infrastructure to assist the platform.
Executives famous that the trouble displays Hua Jian’s broader technique to mix healthcare and know-how, significantly within the distribution layer the place bottlenecks and fraud dangers usually come up.
Why China’s OTC Market Issues
China’s OTC market has been increasing in each city and rural areas as self-care and preventive drugs acquire traction. Business information cited by the businesses suggests this section of healthcare may turn into a significant progress driver within the coming years.
By digitizing and tokenizing OTC drug flows, Hua Jian and Renhe goal to speed up distribution, enhance responsiveness to demand shifts, and scale back friction in retail supply.
Business Implications
Analysts say this partnership may turn into a mannequin for integrating RWAs into pharmaceutical provide chains, a sector historically gradual to adapt to digital innovation.
If profitable, the framework might affect how OTC medication are traded not solely in China but additionally throughout worldwide healthcare markets.
Associated: RWA Crypto Sector Emerges as Day’s Prime Performer with 6.9% Achieve
Disclaimer: The knowledge offered on this article is for informational and academic functions solely. The article doesn’t represent monetary recommendation or recommendation of any sort. Coin Version is just not liable for any losses incurred because of the utilization of content material, merchandise, or companies talked about. Readers are suggested to train warning earlier than taking any motion associated to the corporate.
